Business Context and Reporting Period
Company: Intelligent Bio Solutions Inc. (INBS)
Filing Type: Form 8-K (Current Report)
Date of Report: September 26, 2025
Reporting Period: Single event date (September 26, 2025)
Business Context: The Company is an emerging growth company incorporated in Delaware, trading on The Nasdaq Stock Market LLC. This filing serves as a Regulation FD disclosure regarding a specific regulatory milestone update.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This Form 8-K is a current report focused on a regulatory update and does not contain financial statements or performance metrics.
Material Changes
There are no financial material changes reported in this document. The material event disclosed is an update to the timeline for anticipated FDA 510(k) clearance for the Company's Intelligent Fingerprinting Drug Screening System specifically for the opiate codeine.
Guidance, Outlook, and Management Commentary
- Regulatory Update: Management issued a press release (Exhibit 99.1) on September 26, 2025, providing an update on the timeline for FDA 510(k) clearance for codeine testing.
- Forward-Looking Statements: The disclosure is qualified in its entirety by the full text of the Press Release. The information is furnished and not deemed "filed" under the Exchange Act unless specifically incorporated by reference.
- Risks and Contingencies: The filing does not explicitly detail new risks or contingencies beyond the inherent uncertainty of regulatory timelines implied by the update.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated September 26, 2025) for the specific details of the updated FDA 510(k) clearance timeline for codeine.
- Verify the impact of the codeine clearance timeline on the Company's product roadmap and potential revenue recognition.
- Confirm the Company's status as an emerging growth company and any associated reporting exemptions.
- Check subsequent filings for any further updates on the FDA clearance status or financial implications of the regulatory milestone.